Evidence map›Paper›PMID 25468310›Full record

ReviewJournal of diabetes and its complications2015

Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial.

Jeanie B Tryggestad, Steven M Willi

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of diabetes and its complications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
Open the trial in the graph
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeanie B TryggestadUniversity of Oklahoma Health Sciences Center, 1200 Children's Ave. Suite 4500, Oklahoma City, OK 73104. Electronic address: Jeanie-tryggestad@ouhsc.edu.
Steven M WilliChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, 34th Street & Civic Center Blvd. Suite 11NW30, Philadelphia, PA 19104.

Funding

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) StudyU01DK061230 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI BRAFFETT, BARBARA HALINA, ZEITLER, PHILIP S. · 2001 to 2019
$231.8M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI KATZ, LORRAINE E LEVITT · 2001 to 2008
$6.9M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · NIDDK · YALE UNIVERSITY · PI CAPRIO, SONIA · 2001 to 2008
$5.3M
Treatment Alternatives in Pediatric Type 2 DiabetesU01DK061242 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ZEITLER, PHILIP S. · 2001 to 2008
$5.1M
Type 2 Diabetes in Youth: Beta Cell PreservationU01DK061254 · NIDDK · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · PI ARSLANIAN, SILVA A · 2001 to 2007
$4.1M
NCRR NIH HHS UL1 RR025758NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254NIDDK NIH HHS U01-DK61212NIDDK NIH HHS U01-DK61230NIDDK NIH HHS U01-DK61239NIDDK NIH HHS U01-DK61242NIDDK NIH HHS U01-DK61254
6 · The paper itself

Abstract

With the rise in childhood obesity, type 2 diabetes mellitus (T2DM) has been recognized to occur in adolescents with increasing frequency. Although much is known about T2DM in adults, few studies have examined the treatment and complications of T2DM in youth. The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study was designed to evaluate the efficacy of various treatments and provided a unique opportunity to study the disease progression and appearance of complications in a pediatric cohort with recent onset of the disease. In the TODAY study, hypertension was present in 11.6% of the population at baseline and increased to 33.8% by the end of the study. Prevalence of high-risk LDL-cholesterol rose from 4.5% at baseline to 10.7% at the end of the study. Microalbuminuria was found in 6.3% of the cohort at baseline and increased to 16.6%. Retinopathy was not assessed upon entry into TODAY, but was present in 13.9% of the TODAY cohort at the end of the study. Experience to date indicates that these complications and comorbidities are similar to those seen in adults, but occur on an accelerated timeline. The early manifestation of diabetes complications in youth-onset T2DM suggests that this group will be burdened with the tangible consequences of cardiovascular disease, nephropathy, and retinopathy in the third and fourth decades of life. It is hoped that through an early, aggressive approach to treatment and prevention, we may be able to curb the onset and progression of these potentially devastating outcomes.

Indexed as

Adolescent MedicinePrecision MedicineAdolescentCombined Modality TherapyComorbidityDiabetes ComplicationsDiabetes Mellitus, Type 2Disease ProgressionHumansRandomized Controlled Trials as TopicCardiovascular risk factorsComplicationsNephropathyRetinopathyTreatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) studyType 2 diabetes

Identifiers

PMID25468310
PMCPMC4333013

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.